Kartesia supports Kelso Pharma in its acquisition of ALTURiX

Kartesia, the European specialist provider of financing solutions for small and mid-sized companies, is pleased to announce the provision of committed debt facilities, to support Kelso Pharma (“Kelso”)’s acquisition of ALTURiX (“the Company”) and to fuel Kelso Pharma’s continued M&A strategy.

Kelso Pharma focuses on branded and generic products across various therapeutic areas. By ensuring a consistent supply of such products – often with enhanced formulations which aid patient compliance – Kelso delivers value to healthcare systems. The acquisition of ALTURiX complements Kelso’s current product offering, further strengthening its market position.

Kelso Pharma is backed by Apposite Capital, a UK-based investment firm specialised in healthcare with a strong track record in the sector. With Apposite Capital and Kartesia’s wealth of experience supporting companies across the healthcare sector and commitment to backing growth, Kelso Pharma will be well-equipped to pursue further M&A opportunities, accelerating its strong historical growth trajectory.
Capital for the transaction was deployed from Kartesia’s Senior Opportunities II (KSO II) fund, and the deal team at Kartesia consisted of Nick Holman, Karan Patole and Ana Garcia Vivancos.

Karan Patole, Investment Manager at Kartesia, commented: “We are delighted to support Kelso Pharma on this acquisition as it solidifies its position as a leading provider in the European pharmaceutical sector. We are confident that expanding Kelso’s product offering into further therapeutic areas will enable it to provide continuity of critical products to the NHS and end patients. With the added expertise of the Kelso Pharma team, ALTURiX is also poised for greater success.”

Announcing Kelso Pharma’s third acquisition, Dr. Tom Stratford said: “Our aim has always been to build a specialty pharma business that puts patients first and, in ALTURiX, we have found a complementary business that shares our philosophy of improving the lives of patients in a cost-effective and ethical way. This is a milestone acquisition for Kelso Pharma, doubling the size of our UK business and building a pharma company of scale. The Kelso platform is now positioned for further international growth as we seek to expand the markets for ALTURiX’s products, as well as further enhancing Kelso Pharma’s position as a partner of choice for other pharma businesses and innovative products.”